 |
|
|
| |
New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a (40 kD) induces HBeAg seroconversion/HBsAg loss in patients with HBeAg-positive chronic hepatitis B (The OSST study)
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Q Ning, M Han, Y Sun, J Jiang, D Tan, J Hou, H Tang, J Sheng,
M Zhao
Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China
|
| |
|
|
|
|
|
